Disease damage by system/ organ at last follow up | Frequency (%) |
---|---|
Ocular | 9 (15.3%) |
Cataract | 7 (11.9%) |
Retinal change or optic atrophy | 2 (3.4%) |
Neuropsychiatric | 7 (11.9%) |
Cognitive impairment or major psychosis | 3 (5.1%) |
Seizures requiring therapy for 6 months | 3 (5.1%) |
Cerebrovascular accident ever | 0 |
Cranial or peripheral neuropathy | 1 (1.7%) |
Transverse myelitis | 0 |
Renal | 2 (3.4%) |
Estimated or measured GFR < 50% | 0 |
Proteinuria (nephrotic range proteinuria) | 0 |
End-stage renal disease | 2 (3.4%) |
Pulmonary a | 0 |
Cardiovascular | 2 (3.4%) |
Angina or coronary artery bypass | 0 |
Myocardial infarction ever | 0 |
Cardiomyopathy (ventricular dysfunction) | 2 (3.4%) |
Valvular disease | 0 |
Pericarditis for 6 months | 0 |
Peripheral vascular | 1 (1.7%) |
Claudication for 6 months | 0 |
Minor tissue loss | 0 |
Significant tissue loss ever | 0 |
Venous thrombosis with swelling, ulceration or venous stasis | 1 (1.7%) |
Gastrointestinal b | 0 |
Musculoskeletal | 7 (11.9%) |
Muscle atrophy or weakness | 1 (1.7%) |
Deforming or erosive arthritis | 0 |
Osteoporosis with fracture or vertebral collapse | 0 |
Avascular necrosis (unilateral) | 3 (5.1%) |
Bilateral avascular necrosis | 3 (5.1%) |
Osteomyelitis | 0 |
Skin | 3 (5.1%) |
Scarring chronic alopecia | 0 |
Extensive scarring or panniculum other than scalp and pulp space | 1 (1.7%) |
Skin ulceration for > 6 months | 2 (3.4%) |
Premature gonadal failure | 0 |
Diabetes | 0 |
Malignancy | 0 |